- Top
- Business Overview
- In-house projects
In-house projects
In-house projects with collaboration opportunity are summarized in the following table:
| Target (domain) | Modality | Partner | Status |
TNF-α (immunology)1) |
Small molecule | None | Lead generation stage |
| Runx1-CBFβ (hematology) |
Small molecule | Yokohama City Univ. | Hit validation stage |
|
IL-6 (immunology)2) |
Small molecule | Hirosaki Univ. | Lead generation stage |
|
TIM-3 (oncology; immune checkpoint)3) |
HLHP | None | Hit/lead identification stage |
| Amyloid β (C99) (Alzheimer disease) |
HLHP | Doshisha Univ. | Hit/lead identification stage |
| Smurf1 [E3 ligase] (CV; PAH) |
Small molecule | New York Medical Coll. | Hit validation stage |
|
NKG2A (oncology; immune checkpoint)4) |
HLHP | None | Hit/lead identification stage |
| Tubulin (oncology) | Small molecule | None | Lead generation stage |
| Tumor angiogenesis inhibitor | Small molecule | None | Lead optimization stage |
| Notch1 (oncology, GI) | Small molecule | None | Lead generation stage |
| SARS-CoV-2 (virology) | Small molecule | None |
Drug repurposing (on-going)5)
Drug discovery (planned)6) |
Summary of nonconfidential information on each project of 1)- 6) is disclosed in the separated PDF sheet.